

MiECTiS

3rd MiECT SYMPOSIUM

of the Minimal Invasive Extra Corporeal Technologies International Society

BERN



BERN | SWITZERLAND | 22 – 23 JUNE 2018

**INNOVATION
AND
FUTURE**

WWW.MIECT.ORG

WE HEAR YOU.

INNOVATION

The first thing we do as collaborators is listen. You have shared your experience and expertise, and together, we develop meaningful comprehensive options for your patients.

autoLog IQ™
Autotransfusion System



Spectrum **Medical**
Safer Solutions

Quantum
Perfusion Technologies



autoLog IQ™ is an investigational device that has not been approved for commercial use by regulatory agencies.



3rd MiECT Symposium 22 - 23 June 2018 University Hospital Bern, Switzerland

Scientific Committee: K. Anastasiadis, G. Angelini, P. Antonitsis, A. Bauer, T. Carrel, B. Eberle, S. Gunaydin, E. Gygax, H. Jenni, J. M. Murkin, M. Ranucci

Congress Secretary: P. Libera

22 June 2018

09.00 - 09.15 Course Room 1	Opening Ceremony <i>Thierry Carrel (Bern, CH)</i>
09.15 - 10.00 Course Room 1	Session 1 State of the Art Chairs: <i>Thierry Carrel (Bern, CH), Balthasar Eberle (Bern, CH)</i>
09.15 - 09.30	MiECC; the state of the art in perfusion <i>Kyriakos Anastasiadis (Thessaloniki, GR)</i>
09.30 - 09.45	Minimal Invasive Extracorporeal Circulation Impact on Inflammation and Coagulation <i>Adrian Bauer (Coswig, DE)</i>
09.45 - 10.00	Assessment of Optimization of the Microcirculation: A Strategy for High Risk Patients? <i>John Murkin (Ontario, CA)</i>
10.00 - 11.00 Course Room 1	Session 2 Perfusion techniques Chairs: <i>Polychronis Antonitsis (Thessaloniki, GR), Hansjörg Jenni (Bern, CH)</i>
10.00 - 10.15	MiECT: Concentrating on Safe Perfusion <i>Sybil Serrick (Toronto, CA)</i>
10.15 - 10.30	MICS and MiECC: A necessity <i>Serdan Gunaydin (Ankara, TR)</i>
10.30 - 10.45	From Typ I to Typ III: What are the challenges? <i>Hansjörg Jenni (Bern, CH)</i>
10.45 - 11.00	Podium discussion
11.00 - 11.30	Coffee break <i>Industrial Exhibition</i>



Real Time Monitoring for Early Intervention in CPB

CDI® Blood Parameter Monitoring System 500 and SenSmart™ Model X-100 Universal Oximetry System

Visit our Terumo booth and learn more about the synergies of CDI 500 and SenSmart technology

Contact your local sales representative or call us for further information: Tel: +49(0)6196 80 23 500

Recommended by Clinical Practice Guidelines

Terumo Europe N.V. is the exclusive distributor of SenSmart™ and EQUANOX™ in the UK, Ireland, Germany, France, Netherlands, Belgium, Denmark, Czech Republic, Russia, Sweden, Spain, Portugal, Slovakia & Switzerland. Manufactured in Plymouth, MN, USA by Nonin Medical, Inc. SenSmart™ is a trademark of Nonin Medical, Inc.

©2018 Terumo Europe N.V.
CV205GB-0418OB-III(04.18)E


Terumo® is a registered trademark of Terumo Corporation. CDI® is a registered trademark of Terumo Cardiovascular Systems Corporation.




www.terumo-europe.com

11.30 - 12.45 Course Room 1	Session 3 Cerebral Perfusion and Protection Chairs: <i>Andreas Liebold (Ulm, DE), Balthasar Eberle (Bern, CH)</i>
11.30 - 11.45	Normal NIRS Does Not Mean That Nothing Happened: Limitations of Bifrontal NIRS in Detecting Cerebral Ischemia During Cardiac Surgery. <i>Jan Friess (Bern, CH)</i>
11.45 - 12.00	Monitoring the Brain: Where are we Now <i>John Murkin (Ontario, CA)</i>
12.00 - 12.15	Organ protection strategies in complex aortic arch surgery <i>Christian Schlensak (Tübingen, DE)</i>
12.15 - 12.25	Cognitive perioperative cerebral damage and imaging <i>Marcel Arnold (Bern, CH)</i>
12.25 - 12.35	Podium Discussion
12.35 - 13.15 Industrial Exhibition	Lunchsymposium with Catering (sponsored by Terumo) Minimal Invasive Monitoring in CPB Chairs: <i>Gernot Miemietz (Eschborn, DE)</i>
12.35 - 12.40	Introduction <i>Gernot Miemietz (Eschborn, DE)</i>
12.40 - 12.55	Cerebral rSoCerebral rSO₂: A key parameter for patient adapted perfusion <i>Hansjörg Jenni (Bern, CH)</i>
12.55 - 13.15	Minimizing the impact in CPB on the patient: The relevance of online blood parameter monitoring system <i>Gernot Miemietz (Eschborn, DE)</i>
13.15 - 13.30 Industrial Exhibition	Lunchbreak
13.30 - 14.15 Industrial Exhibition	Lunchsymposium with Catering (sponsored by Medtronic) Simulation in MiECT <i>Hans Sieler</i>
13.45 - 14.00	10 year clinical experience MiECT <i>Annette Smith</i>
14.00 - 14.15	MiECT system of the future <i>Mike van Driel</i>

ThruPort Systems and Edwards Protection Cannulae



EndoVent
Pulmonary Catheter



ProPlege Peripheral Retrograde
Cardioplegia Device



EZ Glide Aortic Cannula



OptiSite Arterial Cannula

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, EndoVent, EZ Glide, OptiSite, ProPlege and Edwards Protection Cannulae are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2018 Edwards Lifesciences Corporation. All rights reserved. E8092/04-18/HVT

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards

14.15 - 15.30 Course Room 1	Session 4 Myocardial and end-organs protection Chairs: <i>Lars Englberger (Bern, CH), Prakash Punjabi (London, UK)</i>
14.15 - 14.30	Goal-directed perfusion in MiECC <i>Apostolos Deliopoulos (Thessaloniki, GR)</i>
14.30 - 14.45	Cardioplexol cardioplegia <i>Hendrik Tevæearai (Zürich, CH)</i>
14.45 - 15.00	Role of cardioplegia: anesthesiologist's view <i>Balthasar Eberle (Bern, CH)</i>
15.00 - 15.15	Podium discussion
15.15 - 15.45 <i>Industrial Exhibition</i>	Coffee break
15.45 - 17.00 Course Room 1	Session 5 Coagulation and inflammation Chairs: <i>Lars Englberger (Bern, CH), John Murkin (Ontario, CA)</i>
15.45 - 16.00	Stress response after heart surgery and clinical illness <i>Gianni Angelini (Bristol, UK)</i>
16.00 - 16.15	Changes in coagulation during minimal-invasive extracorporeal circulation: The role of fibrinogen substitution <i>Gabor Erdoes (Bern, CH)</i>
16.15 - 16.30	CytoSorb Therapy – New options to prevent and treat inflammatory complications in cardiac surgery <i>Christian Napp (Hannover, DE)</i>
16.30 - 16.45	Point of care monitoring of coagulation during minimal-invasive extracorporeal circulation - The role of aggregometry <i>Helena Argiriadou, (Thessaloniki, GR)</i>
16.45 - 17.00	Podium Discussion
17.00 - 17.30 <i>Industrial Exhibition</i>	Coffee break
17.30 - 18.00 Course Room 1	MiECTiS General Assembly
18.00 - 19.00 Course Room 1	COMICS Study
19.30	Festive Evening Kursaal Bern, Forum West



Minimizing the system by continuous integration

MECC-i on Cardiohelp with Quadrox-iR Oxygenator

MECC-i benefits the patient in several respects:

- Closed system, no blood/air contact and less blood trauma
- Reduced foreign body contact
- Low priming volume for less hemodilution
- Bioline Coating for high biocompatibility

www.getinge.com

GETINGE 

This document is intended to provide information to an international audience outside of the US.

23 June 2018

09.00 - 10.35 Course Room 1	Session 6 Miscellaneous
	Chairs: <i>Alexander Kadner (Bern, CH), Urs Zenklusen (Basel, CH)</i>
09.00 - 09.15	Teaching aspects and pitfalls when starting a MiECT programm <i>Alberto Weber (Zürich, CH)</i>
09.15 - 09.30	MiECT for non-coronary surgery <i>Andreas Liebold (Ulm, DE)</i>
09.30 - 09.45	Experience with 2000 cases in Plymouth, UK <i>Clinton Lloyd (Plymouth, UK)</i>
09.45 - 09.55	Superior Cerebral Perfusion with Minimal Invasive Extracorporeal Circulation (MiECC) <i>Rob Bennett (Hull, UK)</i>
09.55 - 10.05	tbd <i>Oz Shapira (Jerusalem, IL)</i>
10.05 - 10.15	MiECC represents the dominant technique in coronary surgery; insights from a health-related economic analysis (QALYs). <i>Polychronis Antonitsis (Thessaloniki, GR)</i>
10.15 - 10.25	Aortic valve replacement with or without myocardial revascularization in octogenarians. Can minimal invasive extracorporeal circuits improve the outcome? <i>Aschraf El-Essawi (Braunschweig, DE)</i>
10.25 - 10.35	The need for conversion from closed to open circuit in the modular (type IV) MiECC systems <i>Polychronis Antonitsis (Thessaloniki, GR)</i>
10.35 - 11.00 <i>Industrial Exhibition</i>	Coffee break

LivaNova

Health innovation that matters

S5™ Min.I.

Mini Maxi Me

Minimized hemodilution,
Maximized benefits

Fully
mast-mounted
pumps
architecture



The proven safe and reliable, world-leading perfusion system,
now optimized for minimally invasive and pediatric surgery

www.livanova.com



Licensed by Eucomed



02295-190/A

11.00 - 12.45 Course Room 1	Session 7 Future Challenges Chairs: <i>Kyriakos Anastasiadis (Thessaloniki, GR),</i> <i>Christof Schmid (Regensburg, DE)</i>
11.00 - 11.10	The importance of monitoring fibrinogen during cardiac surgery on MiECC <i>Helena Argiriadou, (Thessaloniki, GR)</i>
11.10 - 11.20	Initial Clinical Experience with a MiECC System in Pediatric Cardiac Surgery <i>Maris Bartkevics (Bern, CH)</i>
11.20 - 11.30	Antilipidic Reservoir and Antileukocytes with controlled negative pressure an integral part of circuit VS Cell Saver, for the intraoperative recovery of blood loss. <i>Ignazio Condello (Bari, IT)</i>
11.30 - 11.45	The COMICS randomized trial to evaluate MiECT: research questions, trial methods and status <i>Barney Reeves (Bristol, UK)</i>
11.45 - 12.00	The limits of cell salvage <i>Aschraf El-Essawi (Braunschweig, DE)</i>
12.00 - 12.15	Controlled automated reperfusion of the whole body after cardiac arrest <i>Friedhelm Beyersdorf (Freiburg, DE)</i>
12.15 - 12.30	MiECT more physiological - New paradigms in anticoagulation therapy? <i>Yves Fromes (Paris, FR)</i>
12.30 - 12.45	Podium discussion
12.45 - 13.00 Course Room 1	Closing Remarks <i>Thierry Carrel (Bern, CH)</i>



The Congress Committee of the 3rd MiECT Symposium thanks all the industry partners for their precious sponsorship:

Gold Plus Sponsor

Medtronic

Gold Sponsors



Edwards

Bronze Sponsor

- LivaNova

Exhibitors 2018

- CytoSorbents Switzerland GmbH
- Edwards Lifesciences AG
- Getinge
- LivaNova
- Medtronic (Schweiz) AG
- Terumo Europe NV